Akebia Therapeutics Inc (AKBA)

[XenaLives]

Brought back here because of the chart:


SA info lifted from Yahoo convo:

Akebia wins $40M Department of Veterans Affairs contract

Jun. 15, 2021 3:06 PM ETAkebia Therapeutics, Inc. (AKBA)By: Dulan Lokuwithana, SA News Editor
The specialist are doing continuous renal replacement therapy equipment and injection pump.
saengsuriya13/iStock via Getty Images
Akebia Therapeutics (AKBA -3.8%) has been awarded a federal supply contract from the Department of Veterans Affairs. The contract awarded today is valued at $40.2M and runs for five years from July 01, 2021.
The small-cap company, Akebia focused on patients with chronic kidney disease (CKD) saw its net product revenue rise ~4% YoY to $30.4M in Q1 2021.
The company’s topline relies on Auryxia which is approved in the U.S. for the control of serum phosphorus levels in dialysis-dependent CKD adult patients and also for the treatment of iron deficiency anemia in CKD adult patients who are not dependent on dialysis.
The company with its partner, Otsuka Pharmaceutical has sought the marketing approval for vadadustat for the treatment of anemia in adults with CKD irrespective of their dialysis status.